Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Li

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
JCO Precision Oncology|May 14, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian CancerElizabeth M Swisher, Gottfried Konecny, Joshua Cohen, et al.
Chest|May 29, 2020
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort StudyAnish Thomas, Idrees Mian, Camille Tlemsani, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Oncotarget|May 3, 2018
Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinomaJaine K Blayney, Lauren Cairns, Gerald Li, et al.
JAMA|April 10, 2019
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic DatabaseGaurav Singal, Peter G Miller, Vineeta Agarwala, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
JCO Precision Oncology|May 14, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian CancerElizabeth M Swisher, Gottfried Konecny, Joshua Cohen, et al.
Chest|May 29, 2020
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort StudyAnish Thomas, Idrees Mian, Camille Tlemsani, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Oncotarget|May 3, 2018
Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinomaJaine K Blayney, Lauren Cairns, Gerald Li, et al.
JAMA|April 10, 2019
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic DatabaseGaurav Singal, Peter G Miller, Vineeta Agarwala, et al.
Pageof 4